Difference between revisions of "Futibatinib (Lytgobi)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/futibatinib NCI Drug Dictionary]: An orally bioavailable inh...") |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2022-09-30: Granted accelerated approval for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic [[cholangiocarcinoma]] harboring [[Biomarkers#FGFR2|fibroblast growth factor receptor 2 (FGFR2) gene]] [[Biomarkers#fusion|fusions]] or other [[Biomarkers#Rearrangement|rearrangements]]. ''(Based on TAS-120-101)'' |
==Also known as== | ==Also known as== | ||
Revision as of 15:18, 9 May 2023
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 2022-09-30: Granted accelerated approval for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. (Based on TAS-120-101)
Also known as
- Code name: TAS-120
- Brand name: Lytgobi